Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region
Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines
However, regulatory and financial issues will shape when and where this happens
Biosimilars make certain medicines more affordable, but cost and availability drive the need to find ways to improve access
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
National cancer control programmes, pharmaceutical company interest and facilitation of clinical trial participation may be stimulated by epidemiological data
Findings call for a change in tumour categorisation, from a cell-of-origin to a tumour microenvironment-associated holistic approach
Ongoing research will help to clarify how CHIP clones may be used to guide therapy for patients with solid tumours
Research is getting closer to the development of patient-specific tailored treatment approaches for brain tumours, thanks to increased understanding of the tumour microenvironment, including the critical importance of the immune system
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.